USPTO serial 79193398
SGD
Reviewed by CopyMark Law Group
Reg. 5220416Status 708Renewal
- Filing date
- Status date
- Registration date
- Jun 13, 2017
- Examiner
- WHITTAKER BROWN, TRACY
- Law office
- FILE DESTROYED
What this means
This registration is in, or will soon enter, a USPTO maintenance window. Missing a Section 8 or Section 9 filing can cancel the registration.
Need help with SGD?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Renewal, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $548*
Plus Government fees of $1,300
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Jeffrey H. Handelsman
Jeffrey H. Handelsman GREENBLUM & BERNSTEIN, P.L.C.1950 ROLAND CLARKE PLACERESTON, VA 20191-1411UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Chemical preparations for use in industry [ , science and photography, as well as in agriculture, horticulture and forestry; unprocessed artificial resins, unprocessed plastics; fertilizing preparations; fire-extinguishing compositions; tempering preparations for use in and soldering ] ; chemical substances for preserving foodstuffs [ ; tanning agents for use in the manufacture of leather, namely, oils for tanning leather; adhesives for use in industry; alkaloids for industrial purposes; Methyl and Acetic acid esters; acids ] | ACTIVE | — |
| 005 | [ Pharmaceutical, medical and veterinary preparations for treatment of benign prostate hyperplasia, depression, chronic myeloid leukaemia, glaucoma, ocular hypertension, hypertension, hypotension, asthma, schizophrenia, bipolar disorder, diabetes, mental illness, migraines, cough and cold, blood clots, addiction, skin disorders, central nervous system diseases, urinary tract infection; Dietetic substances and foodstuffs for medical and veterinary use, namely, antidepressant for companion animals, lice treatment; Disinfectants, preparations for destroying vermin; Fungicides, herbicides; Alkaloids for medical use; Analgesics; General anesthetics; ] Chemical preparations for medical use [ ; Chemical preparations for pharmaceutical use for treatment of benign prostate hyperplasia, depression, chronic myeloid leukaemia, glaucoma, ocular hypertension, hypertension, hypotension, asthma, schizophrenia, bipolar disorder, diabetes, mental illness, migraines, cough and cold, formation of blood clots, addiction, skin disorders, central nervous system diseases, urinary tract infection; Chemical preparations for veterinary use, namely, for antidepressant for companion animals, lice treatment; Cellulose esters for pharmaceutical use; Hormones for medical use; Potassium salts for medical use, namely, medicated bath salts; Preparations for acne treatments; Controlled substances, namely, prescription narcotics; Opiates; Pharmaceutical preparations, namely, for treatment of benign prostate hyperplasia, depression, chronic myeloid leukaemia, glaucoma, ocular hypertension, hypertension, hypotension, asthma, schizophrenia, bipolar disorder, diabetes, mental illness, migraines, cough and cold, formation of blood clots, addiction, skin disorders, central nervous system diseases, urinary tract infection; Medicine, namely, sulfonamides; Veterinary preparations for treatment of depression for companion animals, lice treatment; Salts for medical use for treatment of benign prostate hyperplasia, depression, chronic myeloid leukaemia, glaucoma, ocular hypertension, hypertension, hypotension, asthma, schizophrenia, bipolar disorder, diabetes, mental illness, migraines, cough and cold, formation of blood clots, addiction, skin disorders, central nervous system diseases, urinary tract infection; Pharmaceutical alcohols, medicinal alcohols; Medicines for human medicine for treatment of benign prostate hyperplasia, depression, chronic myeloid leukaemia, glaucoma, ocular hypertension, hypertension, hypotension, asthma, schizophrenia, bipolar disorder, diabetes, mental illness, migraines, cough and cold, formation of blood clots, addiction, skin disorders, central nervous system diseases, urinary tract infection; Medicines for veterinary use for treatment of depression for companion animals, lice treatment; Medicines for dental use for local anesthetics; Chemical-pharmaceutical preparations for injections for treatment of benign prostate hyperplasia, depression, chronic myeloid leukaemia, glaucoma, ocular hypertension, hypertension, hypotension, asthma, schizophrenia, bipolar disorder, diabetes, mental illness, migraines, cough and cold, formation of blood clots, addiction, skin disorders, central nervous system diseases, urinary tract infection; Chemical preparations for medical or veterinary use for treatment of benign prostate hyperplasia, depression, chronic myeloid leukaemia, glaucoma, ocular hypertension, hypertension, hypotension, asthma, schizophrenia, bipolar disorder, diabetes, mental illness, migraines, cough and cold, formation of blood clots, addiction, skin disorders, central nervous system diseases, urinary tract infection, treatment of depression for companion animals, lice treatment and veterinary preparations for treatment of benign prostate hyperplasia, depression, chronic myeloid leukaemia, glaucoma, ocular hypertension, hypertension, hypotension, asthma, schizophrenia, bipolar disorder, diabetes, mental illness, migraines, cough and cold, blood clots, addiction, skin disorders, central nervous system diseases, urinary tract infection; Dietetic substances and foodstuffs for medical and veterinary use, namely, antidepressant for companion animals, lice treatment; Disinfectants, preparations for destroying vermin; Fungicides, herbicides; Alkaloids for medical use; Analgesics; General anesthetics; Chemical preparations for medical use; Chemical preparations for pharmaceutical use for treatment of benign prostate hyperplasia, depression, chronic myeloid leukaemia, glaucoma, ocular hypertension, hypertension, hypotension, asthma, schizophrenia, bipolar disorder, diabetes, mental illness, migraines, cough and cold, formation of blood clots, addiction, skin disorders, central nervous system diseases, urinary tract infection; Chemical preparations for veterinary use, namely, for antidepressant for companion animals, lice treatment; Cellulose esters for pharmaceutical use; Hormones for medical use; Potassium salts for medical use, namely, medicated bath salts; Preparations for acne treatments; Controlled substances, namely, prescription narcotics; Opiates; Pharmaceutical preparations, namely, for treatment of benign prostate hyperplasia, depression, chronic myeloid leukaemia, glaucoma, ocular hypertension, hypertension, hypotension, asthma, schizophrenia, bipolar disorder, diabetes, mental illness, migraines, cough and cold, formation of blood clots, addiction, skin disorders, central nervous system diseases, urinary tract infection; Medicine, namely, sulfonamides; Veterinary preparations for treatment of depression for companion animals, lice treatment; Salts for medical use for treatment of benign prostate hyperplasia, depression, chronic myeloid leukaemia, glaucoma, ocular hypertension, hypertension, hypotension, asthma, schizophrenia, bipolar disorder, diabetes, mental illness, migraines, cough and cold, formation of blood clots, addiction, skin disorders, central nervous system diseases, urinary tract infection; Pharmaceutical alcohols, medicinal alcohols; Medicines for human medicines for treatment of benign prostate hyperplasia, depression, chronic myeloid leukaemia, glaucoma, ocular hypertension, hypertension, hypotension, asthma, schizophrenia, bipolar disorder, diabetes, mental illness, migraines, cough and cold, formation of blood clots, addiction, skin disorders, central nervous system diseases, urinary tract infection; Medicines for veterinary use for treatment of depression for companion animals, lice treatment; Medicines for dental use for local anesthetics; Chemical-pharmaceutical preparations for injections, treatment of benign prostate hyperplasia, depression, chronic myeloid leukaemia, glaucoma, ocular hypertension, hypertension, hypotension, asthma, schizophrenia, bipolar disorder, diabetes, mental illness, migraines, cough and cold, formation of blood clots, addiction, skin disorders, central nervous system diseases, urinary tract infection; Chemical preparations for medical or veterinary use for treatment of benign prostate hyperplasia, depression, chronic myeloid leukaemia, glaucoma, ocular hypertension, hypertension, hypotension, asthma, schizophrenia, bipolar disorder, diabetes, mental illness, migraines, cough and cold, formation of blood clots, addiction, skin disorders, central nervous system diseases, urinary tract infection, treatment of depression for companion animals, lice treatment ] | ACTIVE | — |
| 040 | [ Treatment of materials in the nature of spry drying, milling, micronisation, nitration, hydrogenation, phosgenation, halogenation, oxidation, reduction; ] [ Custom manufacture of pharmaceutical products per customer order and in accordance with customer requirements; ] [ custom manufacture of pharmaceutical products as per customer order and in accordance with customer requirements, namely, acetal, aldehyds, alkaloids, esters, ketones, mercaptan, oxalates, acids, vitamins and ingredients used in the manufacture of medicines against cancer ] | SECTION 71 - CANCELLED | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Siegfried Holding AG
- Other trademarks owned by Siegfried Holding AG
- Other trademarks owned by Siegfried Holding AG
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 040
- Similar marks named SGD
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jun 13, 2026 | REM4 | COURTESY REMINDER - SEC. 71 (10-YR) E-MAILED | — |
| Mar 12, 2026 | RNWL | INTERNATIONAL REGISTRATION RENEWED | — |
| Sep 27, 2025 | INNP | PARTIAL INVALIDATION PROCESSED BY THE IB | — |
| Sep 2, 2025 | INNA | INVALIDATION REVIEWED - NO ACTION REQUIRED BY OFFICE | — |
| Sep 1, 2025 | INPS | PARTIAL INVALIDATION OF REG EXT PROTECTION SENT TO IB | — |
| Sep 1, 2025 | INPC | INVALIDATION PROCESSED | — |
| May 12, 2025 | INPR | PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED | — |
| Sep 11, 2024 | NA75 | NOTICE OF ACCEPTANCE OF SEC. 71 & 15 - E-MAILED | — |
| Sep 11, 2024 | C75P | REGISTERED - PARTIAL SEC. 71 ACCEPTED & SEC. 15 ACK. | — |
| Apr 9, 2024 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| Aug 3, 2023 | ES75 | TEAS SECTION 71 & 15 RECEIVED | — |
| Jun 23, 2023 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Nov 5, 2022 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Jun 13, 2022 | REM3 | COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED | — |
| Jul 30, 2020 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| May 8, 2019 | INNA | INVALIDATION REVIEWED - NO ACTION REQUIRED BY OFFICE | — |
| Apr 17, 2019 | INPR | PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED | — |
| Aug 17, 2018 | A7OK | AMENDMENT UNDER SECTION 7 - PROCESSED | — |
| Jul 9, 2018 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| Jun 19, 2018 | ES7R | TEAS SECTION 7 REQUEST RECEIVED | — |
| Oct 28, 2017 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Sep 18, 2017 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Sep 18, 2017 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Sep 13, 2017 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Jun 13, 2017 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Mar 28, 2017 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Mar 28, 2017 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Mar 25, 2017 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Mar 8, 2017 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Mar 8, 2017 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Mar 8, 2017 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Feb 21, 2017 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Feb 9, 2017 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Feb 7, 2017 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Feb 7, 2017 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Feb 7, 2017 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Feb 7, 2017 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Jan 26, 2017 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jan 26, 2017 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jan 26, 2017 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 10, 2016 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Dec 10, 2016 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Dec 8, 2016 | ALIE | ASSIGNED TO LIE | — |
| Nov 25, 2016 | RFNT | REFUSAL PROCESSED BY IB | — |
| Nov 22, 2016 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Nov 22, 2016 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Nov 22, 2016 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Nov 9, 2016 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Nov 9, 2016 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Oct 18, 2016 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Oct 15, 2016 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Oct 14, 2016 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 12, 2016 | DOCK | ASSIGNED TO EXAMINER | — |
| Oct 12, 2016 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Oct 6, 2016 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |